GlassScriptPhysician profile
Gaurang Thaker
NPI 1043241433
$3,605.92
in general payments reported to CMS, 2019-2025
32 companies · $749 in 2025
The $749 reported for 2025 was more than what 80% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $201 · 2020: $267 · 2021: $595 · 2022: $363 · 2023: $442 · 2024: $990 · 2025: $749.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,160 · Education: $19.62.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,160.36 |
| Education | $19.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $446.82 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Novo Nordisk INC | $338.91 | 2019-2025 | Ozempic, Rybelsus |
| Pfizer INC. | $311.07 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $308.97 | 2023-2025 | |
| Lilly USA, LLC | $212.28 | 2021-2025 | Zepbound, Mounjaro, Jardiance |
| Abbott Laboratories | $202.96 | 2021-2025 | Freestyle Libre 3 |
| Horizon Therapeutics Plc | $196.42 | 2021-2022 | |
| Astellas Pharma US INC | $142.98 | 2024-2025 | Veozah |
| Boehringer Ingelheim Pharmaceuticals, INC. | $134.57 | 2019-2024 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $133.30 | 2020-2024 | Airsupra, Farxiga |
| Amgen INC. | $127.91 | 2023-2025 | Repatha, Otezla, Repatha |
| Global Blood Therapeutics, INC. | $106.65 | 2020-2021 | |
| Merck Sharp & Dohme LLC | $101.92 | 2020-2022 | |
| Janssen Pharmaceuticals, INC | $89.12 | 2020-2021 | |
| Shield Therapeutics INC | $85.74 | 2023-2024 | Accrufer |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $66.52 | 2020-2021 | |
| Philips North America LLC | $63.88 | 2022-2025 | Ecc Solutions |
| Glaxosmithkline, LLC. | $60.17 | 2024-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Novartis Pharmaceuticals Corporation | $55.82 | 2022 | |
| Biogen, INC. | $48.43 | 2021-2024 | Spinraza |
| Boston Scientific Corporation | $45.43 | 2023-2025 | Bodyguardian |
| Harmony Biosciences LLC | $40.95 | 2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $39.97 | 2025 | Xifaxan |
| Abbvie INC. | $37.67 | 2019-2021 | |
| Nevro Corp. | $37.47 | 2019 | |
| Eisai INC. | $32.90 | 2025 | |
| Neuronetics, INC. | $31.54 | 2025 | Neurostar Tms Therapy System |
| Ars Pharmaceuticals Operations, INC. | $24.07 | 2025 | Neffy |
| Esperion Therapeutics, INC. | $23.16 | 2025 | Nexletol |
| Baxter Healthcare | $22.52 | 2025 | Hillrom - Monarch Airway Clearance System |
| Radius Health, INC. | $20.34 | 2023 | Tymlos |
| Irhythm Technologies, INC. | $15.46 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gaurang Thaker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.